Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.23 USD | -0.23% | -4.74% | -12.38% |
Apr. 16 | QIAGEN NV : Deutsche Bank reiterates its Buy rating | ZD |
Apr. 03 | Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 4.48 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.38% | 8.7B | A | ||
-1.78% | 41.71B | B | ||
+47.70% | 41.56B | A | ||
+4.01% | 39.74B | B- | ||
-15.14% | 25.61B | C | ||
+3.16% | 24.26B | B- | ||
-24.08% | 18.55B | B | ||
-2.67% | 11.93B | C+ | ||
+24.76% | 11.93B | C+ | ||
+7.01% | 10.91B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QGEN Stock
- Ratings Qiagen N.V.